Afinitor (everolimus) vs Trodelvy (sacituzumab govitecan-hziy)
Afinitor (everolimus) vs Trodelvy (sacituzumab govitecan-hziy)
Afinitor (everolimus) is an mTOR inhibitor primarily used to treat certain types of cancers such as advanced renal cell carcinoma, breast cancer, and neuroendocrine tumors, as well as to prevent organ rejection in transplant patients. Trodelvy (sacituzumab govitecan-hziy), on the other hand, is an antibody-drug conjugate specifically indicated for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer after prior therapies. The choice between Afinitor and Trodelvy would depend on the specific type of cancer a patient has, its molecular characteristics, and the previous treatments they have undergone, as each medication targets different pathways and has distinct indications approved by regulatory agencies.
Difference between Afinitor and Trodelvy
| Metric | Afinitor (everolimus) | Trodelvy (sacituzumab govitecan-hziy) |
|---|---|---|
| Generic name | Everolimus | Sacituzumab govitecan-hziy |
| Indications | Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors, renal cell carcinoma, tuberous sclerosis complex-associated seizures, subependymal giant cell astrocytoma, renal angiomyolipoma | Metastatic triple-negative breast cancer, urothelial cancer |
| Mechanism of action | mTOR inhibitor | Antibody-drug conjugate targeting Trop-2 |
| Brand names | Afinitor, Zortress | Trodelvy |
| Administrative route | Oral | Intravenous |
| Side effects | Mouth ulcers, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, pneumonitis | Neutropenia, diarrhea, nausea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash |
| Contraindications | Hypersensitivity to everolimus or other rapamycin derivatives | Hypersensitivity to sacituzumab govitecan-hziy or its excipients |
| Drug class | Immunosuppressant, Antineoplastic agent | Antibody-drug conjugate, Antineoplastic agent |
| Manufacturer | Novartis | Gilead Sciences, Inc. |
Efficacy
Efficacy of Afinitor (Everolimus) in Breast Cancer
Afinitor (everolimus) is a medication that has been shown to be effective in treating hormone receptor-positive, HER2-negative advanced breast cancer. Specifically, it is used in combination with exemestane after the failure of treatment with letrozole or anastrozole. Everolimus works by inhibiting the mTOR pathway, which is a key regulator of tumor cell division, blood vessel growth, and cell metabolism. Clinical trials have demonstrated that Afinitor, when combined with exemestane, significantly extends progression-free survival compared to exemestane alone. However, it is important to note that while Afinitor has been shown to delay the progression of breast cancer, it is not a cure for the disease.
Efficacy of Trodelvy (Sacituzumab Govitecan-hziy) in Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate that has been approved for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. This medication targets the Trop-2 receptor, which is commonly expressed in breast cancer cells, and delivers a potent chemotherapy drug directly to the cancer cells. Clinical studies have shown that Trodelvy significantly improves overall survival and progression-free survival in patients with metastatic TNBC compared to standard single-agent chemotherapies.
Both Afinitor and Trodelvy represent important advancements in the treatment of breast cancer, addressing different subtypes of the disease with distinct mechanisms of action. Their efficacy in improving clinical outcomes for patients with advanced breast cancer highlights the progress being made in targeted and personalized cancer therapy. However, the benefits of these medications must be weighed against their potential side effects, and their use should be guided by a healthcare professional with expertise in oncology.
It is also worth mentioning that ongoing research and clinical trials continue to evaluate the potential of these drugs in various combinations and settings within breast cancer treatment. The landscape of cancer therapy is rapidly evolving, and Afinitor and Trodelvy are part of a growing arsenal of treatments aimed at improving survival and quality of life for patients with breast cancer.
Regulatory Agency Approvals
Afinitor
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
Trodelvy
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Afinitor or Trodelvy today
If Afinitor or Trodelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us